Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Gaitonde P, Huh Y, Heimann G, Li J, Lu K, Benson C, Darpo B, Ferber G, Keirns J, Sebastien B, Tsai K, Wang Y, Zhou M, Riley S (2016) Abstracts accepted for American Conference on Pharmacometrics 2016 (ACoP7). J Pharmacokinet Pharmacodyn 43(1):76.
https://doi.org/10.1007/s10928-016-9485-x
2. Food and Drug Administration (2005) 70 FR 61134—International Conference on Harmonisation; Guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Office of the Federal Register, National Archives and Records Administration.
https://www.gpo.gov/fdsys/granule/FR-2005-10-20/05-20971
3. Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL (2011) Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther 89(1):75–80.
https://doi.org/10.1038/clpt.2010.220
4. Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL (2008) Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin Pharmacol 48(2):215–224.
https://doi.org/10.1177/0091270007311921
5. Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H (2012) The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther 91(2):281–288.
https://doi.org/10.1038/clpt.2011.224
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献